Drugs / PF-06263507
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01891669 | Aug 2013 → Jun 2015 | breast neoplasm, non-small cell lung carcinoma, ovarian neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06263507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01891669 ↗ |
| Route | Intravenous | “PF-06263507 will be administered intravenously in 21-day cycles” NCT01891669 ↗ |
| Target | TPBG | “Trophoblast glycoprotein binding agent” CHEMBL4297804 ↗ |